New York, Blackstone

The Pharma Letter1h
Blackstone builds momentum toward $5 billion biotech fund
Blackstone (NYSE: BX), the world’s largest alternative asset manager, is expanding its presence in the life sciences sector with a new multibillion-dollar fund dedicated to drug development.
Blackstone price target raised to $177 from $174 at Keefe Bruyette
Keefe Bruyette raised the firm’s price target on Blackstone (BX) to $177 from $174 and keeps a Market Perform rating on the shares. Blackstone ...
BX Dips on Real Estate & Data Center Woes, Posts Record Q4 AUM Balance
Despite reporting record Q4 AUM balance and earnings beat, weak Real Estate segment performance & data center concerns drag ...
Blackstone (NYSE:BX) Downgraded to “Hold” Rating by StockNews.com
Blackstone (NYSE:BX – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Other research analysts have also ...
Blackstone turns in Q4 earnings beat as inflows, investment activity revive
Blackstone (BX), the private equity giant, delivered stronger-than-expected Q4 earnings on Thursday, as assets under ...
Blackstone to Present at the Bank of America Securities Financial Services Conference 2025
Blackstone (NYSE:BX) announced today that Michael Chae, Vice Chairman and Chief Financial Officer, is scheduled to present at ...
Blackstone Inc. (BX) Acquires Potomac Energy Center to Power AI Revolution and Data Centers in Virginia
We recently compiled a list of the 10 AI News Updates Investors Should Not Miss. In this article, we are going to take a look ...
Blackstone’s BREIT hole keeps growing
To recap, the Blackstone Real Estate Investment Income Trust was a commercial juggernaut in the ZIRP era, growing to nearly ...